Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT04786093 | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05812274 |
| Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients |
| terminated |
| N/A |
| 30 |
| Columbia UniversityOTHER |
| 1 |
| May 5, 2026 |
| clinicaltrials |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | terminated | Phase 1 | 68 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT06192004 | Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD(LOOP) | terminated | — | 83 | AstraZenecaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06235242 | GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer | terminated | N/A | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06513663 | Exercise as Maintenance Therapy in Advanced Lung Cancer | terminated | N/A | 2 | Indiana UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma | terminated | Phase 1 | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | terminated | Phase 1 | 8 | PfizerINDUSTRY | 2 | Apr 23, 2026 | clinicaltrials |
| NCT02257619 | Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Incyte CorporationINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02298153 | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma | terminated | Phase 1 | 29 | Incyte CorporationINDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | terminated | Phase 1 | 21 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | terminated | Phase 1 | 1 | Instil BioINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer | terminated | Phase 1 / Phase 2 | 6 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | terminated | Phase 1 | 91 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02679963 | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer(PIPSeN) | terminated | Phase 2 | 180 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03348748 | Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer | terminated | Early Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05765734 | A Study of TAS3351 in NSCLC Patients With EGFRmt(TAS3351) | terminated | Phase 1 | 18 | Taiho Oncology, Inc.INDUSTRY | 5 | Apr 2, 2026 | clinicaltrials |
| NCT06186076 | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients | terminated | Phase 1 / Phase 2 | 19 | Therapex Co., LtdINDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | terminated | Phase 1 | 24 | Imugene LimitedINDUSTRY | 2 | Mar 25, 2026 | clinicaltrials |
| NCT04911166 | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy | terminated | Phase 1 | 13 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation(ALAFOSS-01) | terminated | Phase 1 | 17 | AstraZenecaINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT03265496 | Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation(CONCORDE) | terminated | N/A | 21 | Centre Oscar LambretOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06083454 | Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 1 | William ZeitlerOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06173505 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | terminated | Phase 1 / Phase 2 | 28 | Xencor, Inc.INDUSTRY | 8 | Mar 13, 2026 | clinicaltrials |
| NCT05636267 | Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | terminated | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)(AcceleRET-Lung) | terminated | Phase 3 | 223 | Hoffmann-La RocheINDUSTRY | 22 | Mar 5, 2026 | clinicaltrials |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | terminated | Phase 1 | 29 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04880382 | Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients(OPTIMUNELUNG) | terminated | Phase 2 | 8 | Institut BergoniéOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03066206 | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | terminated | Phase 2 | 93 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03366766 | Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 21 | PfizerINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | terminated | Phase 1 | 64 | Mirati Therapeutics Inc.INDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 30 | Novartis PharmaceuticalsINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT03559049 | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 25 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT05443971 | Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04081688 | Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC | terminated | Phase 1 | 16 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04836429 | Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease | terminated | Phase 1 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 1 | 42 | Prelude TherapeuticsINDUSTRY | 6 | Feb 2, 2026 | clinicaltrials |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 2 | 6 | Prelude TherapeuticsINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT03436056 | PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients(PRIMING) | terminated | Phase 1 | 2 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 8, 2026source: clinicaltrials